Literature DB >> 1916510

Presentation of cervical cancer.

R Pretorius1, N Semrad, W Watring, N Fotheringham.   

Abstract

To determine how patients with invasive cervical cancer present and whether presentation affects disease-free survival (DFS), a review of 81 patients treated for cervical cancer by the Division of Gynecologic Oncology and Pelvic Surgery at the Southern California Permanente Medical Group between January 1, 1986, and December 31, 1986, was performed. Fifty-six percent of patients presented with abnormal vaginal bleeding, twenty-eight percent presented with abnormal Papanicolaou (Pap) smears, nine percent presented with pain, four percent presented with vaginal discharge, and four percent presented with other symptoms. Follow-up was 24 to 41 months. Patients presenting with abnormal Pap smears had DFS of 96%. Those presenting with abnormal vaginal bleeding had DFS of 51% and those presenting with pain had DFS of 29%. Presentation strongly influences DFS (chi 2 = 16.8, P less than 0.001). Of women presenting with abnormal Pap smears, 87% were Stage I and 13% were Stage II. Of women presenting with other than abnormal Pap smears, 40% were Stage I, 34% were Stage II, and 26% were Stage III or IV. Presentation with abnormal Pap smear and stage are significantly related (chi 2 = 14.8, P less than 0.001). Of women presenting with abnormal Pap smears, 89% had cancers 0 to 2 cm, 5% had cancers 2.1 to 4 cm, and 5% had cancers greater than 4 cm in diameter. Of women presenting with other than abnormal Pap smears, 21% had cancers 0 to 2 cm, 26% had cancers 2.1 to 4 cm, and 53% had cancers greater than 4 cm in diameter. Presentation with abnormal Pap smear is significantly associated with tumor size (chi 2 = 25.4, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1916510     DOI: 10.1016/0090-8258(91)90229-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Will HPV vaccination affect cervical cancer morbidity and mortality world-wide?

Authors:  Rebecca Luckett; Sarah Feldman
Journal:  Hum Vaccin Immunother       Date:  2016-06-02       Impact factor: 3.452

Review 2.  A systematic review of postcoital bleeding and risk of cervical cancer.

Authors:  Mark Shapley; Joanne Jordan; Peter R Croft
Journal:  Br J Gen Pract       Date:  2006-06       Impact factor: 5.386

Review 3.  Postcoital bleeding: a review on etiology, diagnosis, and management.

Authors:  Christopher M Tarney; Jasmine Han
Journal:  Obstet Gynecol Int       Date:  2014-06-17

4.  Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study.

Authors:  Anita W Lim; Amanda J Ramirez; William Hamilton; Peter Sasieni; Julietta Patnick; Lindsay Jl Forbes
Journal:  Br J Gen Pract       Date:  2014-10       Impact factor: 5.386

5.  The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients.

Authors:  Sara Bønløkke; Magnus Stougaard; Boe Sandahl Sorensen; Berit Bargum Booth; Estrid Høgdall; Gitte-Bettina Nyvang; Jacob Christian Lindegaard; Jan Blaakær; Jesper Bertelsen; Katrine Fuglsang; Mikael Lenz Strube; Suzan Lenz; Torben Steiniche
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

6.  Assessment of excessive vaginal discharge among women who presented to Phuentsholing General Hospital: A hospital-based study.

Authors:  Yeshey Dorjey; Dechen Wangmo; Dechen Tshomo
Journal:  Health Sci Rep       Date:  2022-09-01

7.  Measuring the nature and duration of symptoms of cervical cancer in young women: developing an interview-based approach.

Authors:  Anita W W Lim; Lindsay J L Forbes; Adam N Rosenthal; Kantipati S Raju; Amanda-Jane Ramirez
Journal:  BMC Womens Health       Date:  2013-11-13       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.